Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma.
about
NTRK gene fusions as novel targets of cancer therapy across multiple tumour typesSystemic Therapy in Metastatic or Unresectable Well-Differentiated/Dedifferentiated Liposarcoma.Clinical and Molecular Spectrum of Liposarcoma.Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.
P2860
Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Significant blockade of multip ...... preclinical models of sarcoma.
@en
Significant blockade of multip ...... preclinical models of sarcoma.
@nl
type
label
Significant blockade of multip ...... preclinical models of sarcoma.
@en
Significant blockade of multip ...... preclinical models of sarcoma.
@nl
prefLabel
Significant blockade of multip ...... preclinical models of sarcoma.
@en
Significant blockade of multip ...... preclinical models of sarcoma.
@nl
P2093
P2860
P356
P1433
P1476
Significant blockade of multip ...... preclinical models of sarcoma.
@en
P2093
Elgilda Musi
Gary K Schwartz
Kathryn S Ivy
Parag P Patwardhan
P2860
P304
P356
10.18632/ONCOTARGET.6547
P407
P577
2015-12-10T00:00:00Z